Cancer Chemotherapy and Pharmacology

, Volume 57, Issue 3, pp 295–300 | Cite as

Phosphatidylcholine-associated nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit DNA synthesis and the growth of colon cancer cells in vitro

  • Elizabeth J. Dial
  • J. Rand Doyen
  • Lenard M. Lichtenberger
Original Article

Abstract

The use of NSAIDs or COX-2 inhibitors for chemoprevention of colorectal cancer has been suggested for patients at high risk for this disease. However, the gastrointestinal side effects of traditional NSAIDs which consist of bleeding and ulceration, and the cardiovascular effects of COX-2 inhibitors may limit their usefulness. In preclinical studies, our laboratory has shown that the addition of phosphatidylcholine (PC) to the NSAIDs aspirin (ASA) or ibuprofen (IBU) results in a NSAID–PC with fewer GI side effects and also maintained or enhanced analgesic, anti-pyretic and anti-inflammatory efficacy over the unmodified NSAID. Because NSAID–PCs have not been tested for anti-cancer activity, in the present study, ASA–PC and IBU–PC were tested on the SW-480 human colon cancer cell line. SW-480 cells were incubated in media containing 1–5 mM NSAID or NSAID–PC for 2 days. Measurements were made of cell number, cell proliferation (DNA synthesis), and manner of cell death (necrosis and apoptosis). ASA and IBU reduced cell number in a dose-dependent manner with IBU showing a greater potency than ASA. The association of PC to the NSAID resulted in greater reductions of cell number for both NSAIDs. Furthermore, the NSAID–PC formulation had significantly greater efficacy and potency to inhibit cellular DNA synthesis than the unmodified NSAID. PC alone at the doses and times used had no effect on cell number in this cell line, but did have a small effect to reduce DNA synthesis. None of the drugs had a clear effect on cell death by necrosis. Only IBU and IBU–PC caused cell death by apoptosis in SW-480 cells. We conclude that NSAID–PCs have activity to impede the growth of colon cancer cells in vitro, which is due, in major part, to a marked reduction in DNA synthetic activity of these cells. This growth inhibitory effect appears to be independent of COX-2 activity, since it is known that SW-480 cells do not have this inducible COX isoform. Due to its greater efficacy in this model system, IBU–PC should be further evaluated as a chemopreventive agent that is safer for the GI tract than unmodified NSAID.

Keywords

NSAID Phosphatidylcholine Colon cancer Aspirin Ibuprofen 

Notes

Acknowledgements

This project was supported in part by PHS DK56338 which funds the Texas Gulf Coast Digestive Diseases Center.

References

  1. 1.
    Anand BS, Romero JJ, Sanduja SK, Lichtenberger LM (1999) Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am J Gastroenterol 94:1818–1822PubMedCrossRefGoogle Scholar
  2. 2.
    Awad AB, Ntanios FY, Fink CS, Horvath PJ (1996) Effect of membrane lipid alteration on the growth, phospholipase C activity and G protein of HT-29 tumor cells. Prostaglandins Leukot Essent Fatty Acids 55:293–302PubMedCrossRefGoogle Scholar
  3. 3.
    Baek SJ, Wilson LC, Lee Ch, Eling TE (2002) Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 301:1126–1131PubMedCrossRefGoogle Scholar
  4. 4.
    Bonnekoh B, Roding J, Krueger GR, Ghyczy M, Mahrle G (1991) Increase of lipid fluidity and suppression of proliferation resulting from liposome uptake by human keratinocytes in vitro. Br J Dermatol 124:333–340PubMedCrossRefGoogle Scholar
  5. 5.
    Corpetti G, Rosignoli MT, Dionisio P (1998) Comparative bioavailability study of two oral formulations of ibuprofen. Arzneimittelforschung 48:392–395PubMedGoogle Scholar
  6. 6.
    Cryer B, Feldman M (1999) Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 117:17–25PubMedCrossRefGoogle Scholar
  7. 7.
    Eberhart CE, Coffey RJ, Radhika A, Giardiello Fm, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183–1188PubMedGoogle Scholar
  8. 8.
    FitzGerald GA (2004) Coxibs and cardiovascular disease. N Engl J Med 351:1709–1711CrossRefPubMedGoogle Scholar
  9. 9.
    Gabriel SE, Jaakkimainen L, Bombardier C (1991) Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 115:787–796PubMedGoogle Scholar
  10. 10.
    Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC (1994) Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121:241–246PubMedGoogle Scholar
  11. 11.
    Goel A, Chang DK, Ricciardiello L, Gasche C, Boland CR (2003) A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res 9:383–390PubMedGoogle Scholar
  12. 12.
    Gantarz N, Small RE, Comstock TJ, Stalker DJ, Johnson SM, Willis HE (1987) Effect of antacid suspension on the pharmacokinetics of ibuprofen. Clin Pharm 6:413–416PubMedGoogle Scholar
  13. 13.
    Gupta RA, Dubois RN (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1:11–21CrossRefPubMedGoogle Scholar
  14. 14.
    Hixson LJ, Alberts DS, Krutzsch M, Einsphar J, Brendel K, Gross PH, Paranka NS, Baier M, Emerson S, Pamukcu R, Burt RW (1994) Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol Biomarkers Prev 3:433–438PubMedGoogle Scholar
  15. 15.
    Lichtenberger LM, Wang ZM, Romero JJ, Ulloa C, Perez JC, Giraud MN, Barreto JC (1995) Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med 1:154–158CrossRefPubMedGoogle Scholar
  16. 16.
    Lichtenberger LM, Ulloa C, Vanous AL, Romero JJ, Dial EJ, Illich PA, Walters ET (1996) Zwitterionic phospholipids enhance aspirin’s therapeutic activity, as demonstrated in rodent model systems. J Pharmacol Exp Ther 277:1221–1227PubMedGoogle Scholar
  17. 17.
    Lichtenberger LM, Romero JJ, De Ruijter WM, Behbod F, Darling R, Ashraf AQ, Sanduja SK (2001) Phosphatidylcholine association increases the anti-inflammatory and analgesic activity of ibuprofen in acute and chronic rodent models of joint inflammation: relationship to alterations in bioavailability and cyclooxygenase-inhibitory potency. J Pharmacol Exp Ther 298:279–287PubMedGoogle Scholar
  18. 18.
    Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306–1311PubMedGoogle Scholar
  19. 19.
    Muscat JE, Stellman DS, Wynder EL (1994) Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 74:1847–1854PubMedCrossRefGoogle Scholar
  20. 20.
    Nath N, Kashfi K, Chen J, Rigas B (2003) Nitric oxide-donating aspirin inhibits β–catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear β–catenin-TCF association. PNAS 100:12584–12589CrossRefPubMedGoogle Scholar
  21. 21.
    Sachinidis A, Carniel M, Seewald S, Seul C, Gouni-Berthold I, Ko Y, Vetter H (1999) Lipid-induced changes in vascular smooth muscle cell membrane fluidity are associated with DNA synthesis. Cell Prolif 32:101–105PubMedCrossRefGoogle Scholar
  22. 22.
    Shah A, Woodruff M, Agarwal V, Liu P, Sundaresan P (2001) Pharmacokinetics, safety, and tolerability of BAY 12–9566 and nonsteroidal anti-inflammatory agents (naproxen, ibuprofen) during coadministration in patients with osteroarthritis. J Clin Pharmacol 41:330–339PubMedCrossRefGoogle Scholar
  23. 23.
    Smith M-L, Hawcroft G, Hull MA (2000) The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanism of action. Eur J Cancer 36:664–674CrossRefPubMedGoogle Scholar
  24. 24.
    Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B (2000) The effects of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952CrossRefPubMedGoogle Scholar
  25. 25.
    Suh O, Mettlin C, Petrelli NJ (1993) Aspirin use, cancer, and polyps of the large bowel. Cancer 72:1171–1177PubMedCrossRefGoogle Scholar
  26. 26.
    Tegeder I, Pfeilschifter J, Geisslinger G (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15:2057–2072CrossRefPubMedGoogle Scholar
  27. 27.
    Thun MJ, Namboodiri MM, Heath CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593–1596PubMedCrossRefGoogle Scholar
  28. 28.
    Wargovich MJ, Chen CD, Harris C, Yang E, Velasco M (1995) Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon. Int J Cancer 60:515–519PubMedCrossRefGoogle Scholar
  29. 29.
    Wargovich MJ, Chen CD, Jimenez A, Steele VE, Velasco M, Stephens LC, Price R, Gray K, Kelloff GJ (1996) Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol Biomarkers Prev 5:355–360PubMedGoogle Scholar
  30. 30.
    Williams JL, Borgo S, Hasan I, Castillo E, Tragonos F, Rigas B (2001) Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention. Cancer Res 61:3285–3289PubMedGoogle Scholar
  31. 31.
    Yao M, Zhow W, Sangha S, Wolfe MM (2004) Ibuprofen attenuates tumor growth and liver metastasis and enhances efficacy of chemotherapy in colorectal cancer. Gastroenterology 126:A101Google Scholar
  32. 32.
    Yeh RK, Chen J, Williams JL, Baluch M, Hundley TR, Rosenbaum RE, Kalala S, Tragonos F, Benardini F, Soldato P, Kashfi K, Rigas B (2004) NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem Pharmacol 67:2197–2205CrossRefPubMedGoogle Scholar
  33. 33.
    Yu H-G, Huang J-A, Yang Y-N, Huang H, Luo H-S, Yu J-P, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F (2002) The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells. Eur J Clin Invest 32:838–846CrossRefPubMedGoogle Scholar
  34. 34.
    Yu H-G, Huang J-A, Yang Y-N, Luo H-S, Yu J-P, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F (2003) Inhibition of cytosolic phospholipase A2 mRNA expression: a novel mechanism for acetylsalicylic acid-mediated growth inhibition and apoptosis in colon cancer cells. Reg Peptides 114:101–107CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Elizabeth J. Dial
    • 1
  • J. Rand Doyen
    • 1
  • Lenard M. Lichtenberger
    • 1
  1. 1.Department of Integrative Biology and PharmacologyThe University of Texas Medical SchoolHoustonUSA

Personalised recommendations